Ownership and insider activity for Cellectar Biosciences, Inc. (CLRB): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.
Price
| Price | $2.35 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-08 | Loren Stefan | A-Award | 15,000 | $40K |
| 2026-07-07 | Kolean Chad J | A-Award | 92,000 | $289K |
| 2026-07-07 | DRISCOLL FREDERICK W | A-Award | 25,000 | $68K |
| 2026-07-07 | Chanan-Khan Asher | A-Award | 25,000 | $68K |
| 2026-07-07 | CARUSO JAMES V | A-Award | 250,000 | $785K |
| 2026-07-07 | Gu Andrew | A-Award | 25,000 | $68K |
| 2026-07-07 | Longcor Jarrod | A-Award | 118,000 | $371K |
| 2026-07-07 | Swirsky Douglas J | A-Award | 37,500 | $101K |
| 2026-07-07 | NEIS JOHN | A-Award | 25,000 | $68K |
| 2026-07-08 | Loren Stefan | A-Award | 15,000 | $40K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.4M | $10.0M | $13.3M | $10.6M | $57.2M | $35.7M | $19.9M | $9.6M | $23.3M | $13.2M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $12.2M | $10.5M | $14.0M | $11.4M | $57.9M | $36.6M | $20.5M | $10.5M | $24.3M | $14.0M |
| Property, Plant & Equipment | $1.4M | $244713 | $543339 | $783924 | $638347 | $549135 | $978975 | $1.6M | $1.2M | $910076 |
| Goodwill | $1.7M | $1.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $15.3M | $12.9M | $15.1M | $12.3M | $58.7M | $37.2M | $21.6M | $12.1M | $25.5M | $15.0M |
| Accounts Payable | $1.4M | $1.9M | $1.5M | $1.3M | $1.4M | $1.4M | $2.6M | $5.6M | $4.1M | $1.4M |
| Short-term Debt | $86591 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.6M | $2.1M | $1.6M | $2.8M | $3.6M | $4.0M | $11.5M | $25.4M | $9.4M | $4.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $1.8M | $2.1M | $1.8M | $3.2M | $3.9M | $4.2M | $12.1M | $25.9M | $11.2M | $5.1M |
| Retained Earnings | -$70.8M | -$84.3M | -$97.6M | -$111.7M | -$126.8M | -$150.9M | -$160.0M | -$202.8M | -$247.3M | -$269.1M |
| Total Equity | $13.5M | $10.8M | $13.3M | $9.1M | $54.8M | $33.0M | $9.5M | -$13.8M | $14.3M | $9.9M |
| Total Debt | $94567 | $5249 | $2213 | $527529 | $421644 | $301741 | $603828 | $552982 | $494003 | $409586 |
| Net Debt | -$11.4M | -$10.0M | -$13.3M | -$10.1M | -$56.7M | -$35.4M | -$19.3M | -$9.0M | -$22.8M | -$12.8M |
| Working Capital | $10.6M | $8.4M | $12.3M | $8.6M | $54.4M | $32.6M | $9.0M | -$14.9M | $14.9M | $9.3M |
Financial Health
| Debt / Equity | 0.05 |
| Current Ratio | 6.66 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -28.56 |
Profitability
| Return on Equity | -165.71% |
| Return on Invested Capital | -74.93% |
| Return on Assets | -60.93% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AEON · BOLT · CING · EVGN · IMNN · LYRA · MBIO
Explore sector: Healthcare · Biotechnology
More sections of CLRB: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks